Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Treatment
Zalypsis for solid tumors enters clinical development
February 20th, 2005
PharmaMar announced that Zalypsis (PM00104/50), its fifth new marine-derived compound, has begun phase I clinical trials, already in patients, for the treatment of solid tumors. Zalypsis is a novel chemical entity related to the marine natural compounds Jorumycin and the family of Renieramycins, obtained from molluscs and sponges, respectively. Zalypsis binds to DNA and is cytotoxic; however, it does not activate the "DNA damage checkpoint" response. Thus, Zalypsis has cytotoxic effects dependent on DNA binding that are not associated with DNA damage. In preclinical trials, Zalypsis demonstrated strong in vitro and in vivo antitumoral activity in a...
Source: Medical Letter on the CDC & FDA (2005-02-20)
|
